| | Commentaries How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial Vernon VS Bonarjee and Kenneth Dickstein Curr Control Trials Cardiovasc Med. 2001; 2(4): 151–155. Published online 2001 June 26. doi: 10.1186/cvm-2-4-151.PMCID: PMC59642 Dose response of ACE inhibitors: implications of the SECURE trial Eva Lonn Curr Control Trials Cardiovasc Med. 2001; 2(4): 155–159. Published online 2001 July 6. doi: 10.1186/cvm-2-4-155.PMCID: PMC59639 Organizing the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST): National Institutes of Health, Health Care Financing Administration, and industry funding Robert W Hobson, II, Virginia J Howard, Thomas G Brott, George Howard, Gary S Roubin, Robert DG Ferguson, and for the CREST Executive Committee Curr Control Trials Cardiovasc Med. 2001; 2(4): 160–164. Published online 2001 July 13. doi: 10.1186/cvm-2-4-160.PMCID: PMC59640 Reviews The role of dyslipidemia and statins in venous thromboembolism Joel G Ray and Frits R Rosendaal Curr Control Trials Cardiovasc Med. 2001; 2(4): 165–170. Published online 2001 July 20. doi: 10.1186/cvm-2-4-165.PMCID: PMC59643 Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease Jassim Al Suwaidi and Amar M Salam Curr Control Trials Cardiovasc Med. 2001; 2(4): 171–179. Published online 2001 July 26. doi: 10.1186/cvm-2-4-171.PMCID: PMC59641 Research Systematic adjudication of myocardial infarction end-points in an international clinical trial Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol, Robert M Califf, and for the PURSUIT Investigators Curr Control Trials Cardiovasc Med. 2001; 2(4): 180–186. Published online 2001 July 17. doi: 10.1186/cvm-2-4-180.PMCID: PMC57749 Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study Kenneth W Mahaffey, Robert A Harrington, Martijn Akkerhuis, Neal S Kleiman, Lisa G Berdan, Brian S Crenshaw, Barbara E Tardiff, Christopher B Granger, Ingrid DeJong, Manju Bhapkar, Petr Widimsky, Ramón Corbalon, Kerry L Lee, Jaap W Deckers, Maarten L Simoons, Eric J Topol, Robert M Califf, and for the PURSUIT Investigators Curr Control Trials Cardiovasc Med. 2001; 2(4): 187–194. Published online 2001 July 17. doi: 10.1186/cvm-2-4-187.PMCID: PMC57750 Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621] Thomas W Meade and for the British Medical Research Council General Practice Research Framework and participating vascular clinics Curr Control Trials Cardiovasc Med. 2001; 2(4): 195–204. Published online 2001 July 23. doi: 10.1186/cvm-2-4-195.PMCID: PMC57751 |